Clinically, STAR-0215 demonstrated a long circulating half-life (estimated 117 days) and prolonged plasma kallikrein inhibition (at least 84 days). Simulation of different dose regimens was performed using a mechanistic quantitative systems pharmacology (QSP) model to explore the potential for the reduction of HAE attacks. The gene discussed is KLK4; the disease is hereditary angioedema.